GLAND - Fundamental Analysis: Financial Health & Valuation

Last Updated Time : 19 Sept 25, 2:16 pm

Fundamental Rating: 4.0

📊 Core Financials Breakdown

Profitability

ROE: 11.6% and ROCE: 15.8% — solid, though not exceptional for a pharma company.

EPS: ₹69.0 — strong earnings base, supporting a healthy P/E ratio.

PAT Qtr: ₹269 Cr vs ₹290 Cr — slight dip, but still shows 20.8% YoY growth.

Balance Sheet & Leverage

Debt-to-Equity: 0.00 — debt-free, a major strength in a capital-intensive sector.

Book Value: ₹592 — implies a P/B ratio of ~3.4, reasonable given the quality metrics.

Dividend Yield: 0.89% — modest, but consistent.

💰 Valuation Metrics

Metric Value Comment

P/E Ratio 29.2 Slightly below industry average (33.4) — fair valuation

PEG Ratio -8.53 Negative PEG suggests caution — likely due to earnings volatility or forecast uncertainty

Intrinsic Value ~₹1,950–₹2,050 CMP is near fair value zone

Valuation is reasonable, though PEG ratio flags potential growth concerns.

💊 Business Model & Competitive Edge

Sector: Pharmaceuticals — focused on sterile injectables and complex generics.

Strengths

Strong global footprint — US, Europe, Canada, Australia, and emerging markets.

Recent USFDA approvals for Vasopressin and Cangrelor injections

1

.

GMP certification for Pashamylaram facility boosts regulatory credibility

1

.

FII holding up (+0.49%) — positive institutional sentiment.

Challenges

DII holding down (-0.41%) — some caution from domestic institutions.

PEG ratio and slight PAT decline suggest margin pressure or slower growth.

📉 Technicals & Entry Zone

Current Price: ₹2,018

DMA 50: ₹1,915 | DMA 200: ₹1,772 — bullish trend intact

RSI: 62.1 — nearing overbought zone

MACD: Positive — momentum strong

📌 Suggested Entry Zone: ₹1,850–₹1,950

A dip near the 50 DMA would offer a better margin of safety for accumulation.

🧭 Long-Term Holding Guidance

Hold if invested: Strong fundamentals, global approvals, and zero debt make GLAND a solid long-term play.

Accumulate on dips: Ideal for investors seeking exposure to high-margin injectables and global pharma expansion.

You can explore Gland Pharma’s full financials and analyst views or review its technical chart and valuation metrics for deeper insights. Let me know if you'd like a peer comparison with Divi’s Labs or Syngene.

1

stockanalysis.com

Edit in a page